Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

(Reuters) - An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy ...

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for ...

While conventional treatments such as chemotherapy and radiotherapy show their limitations in battling certain advanced cancers, immunotherapy and therapeutic vaccines have opened up a new realm of ...

Moderna (MRNA) announced an update on their ongoing clinical study. This phase 3 trial, officially titled “A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity ...

Study Overview: Merck and Moderna are running a Phase 2 trial called “A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk ...

VANCOUVER, BC, Dec. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine ...

An experimental mRNA cancer vaccine developed by Moderna and Merck cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S.